Figure 3From: Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder Percentage of participants optimized to each dose, among participants who completed dose optimization (n=327). Percentages have been rounded; total tally may not equal 100%. Abbreviations: d=day; LDX=lisdexamfetamine dimesylate.Back to article page